Cost-Effectiveness of Pharmacogenetics-Guided Warfarin Therapy vs. Alternative Anticoagulation in Atrial Fibrillation
出版年份 2013 全文链接
标题
Cost-Effectiveness of Pharmacogenetics-Guided Warfarin Therapy vs. Alternative Anticoagulation in Atrial Fibrillation
作者
关键词
-
出版物
CLINICAL PHARMACOLOGY & THERAPEUTICS
Volume 95, Issue 2, Pages 199-207
出版商
Springer Nature
发表日期
2013-09-25
DOI
10.1038/clpt.2013.190
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Cost-Effectiveness of Using Pharmacogenetic Information in Warfarin Dosing for Patients With Nonvalvular Atrial Fibrillation
- (2013) Mark H. Eckman ANNALS OF INTERNAL MEDICINE
- Comparative Effectiveness of Dabigatran, Rivaroxaban, Apixaban, and Warfarin in the Management of Patients With Nonvalvular Atrial Fibrillation
- (2013) J Pink et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- A Randomized and Clinical Effectiveness Trial Comparing Two Pharmacogenetic Algorithms and Standard Care for Individualizing Warfarin Dosing (CoumaGen-II)
- (2012) Jeffrey L. Anderson et al. CIRCULATION
- New Oral Anticoagulants for Atrial Fibrillation: A Review of Clinical Trials
- (2012) Kate M. O'Dell et al. CLINICAL THERAPEUTICS
- Dabigatran Etexilate
- (2012) Kate McKeage PHARMACOECONOMICS
- Cost-Effectiveness of Dabigatran versus Genotype-Guided Management of Warfarin Therapy for Stroke Prevention in Patients with Atrial Fibrillation
- (2012) Joyce H. S. You et al. PLoS One
- Influence of CYP2C9 and VKORC1 on Patient Response to Warfarin: A Systematic Review and Meta-Analysis
- (2012) Andrea L. Jorgensen et al. PLoS One
- Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C9 and VKORC1 Genotypes and Warfarin Dosing
- (2011) J A Johnson et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Apixaban versus Warfarin in Patients with Atrial Fibrillation
- (2011) Christopher B. Granger et al. NEW ENGLAND JOURNAL OF MEDICINE
- Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation
- (2011) Manesh R. Patel et al. NEW ENGLAND JOURNAL OF MEDICINE
- Integration of Genetic, Clinical, and INR Data to Refine Warfarin Dosing
- (2010) P Lenzini et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- A Pharmacometric Model Describing the Relationship Between Warfarin Dose and INR Response With Respect to Variations in CYP2C9, VKORC1, and Age
- (2010) A-K Hamberg et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Prospective alpha allocation in the clarification of optimal anticoagulation through genetics (COAG) trial
- (2010) Jungnam Joo et al. Clinical Trials
- Effect of Home Testing of International Normalized Ratio on Clinical Events
- (2010) David B. Matchar et al. NEW ENGLAND JOURNAL OF MEDICINE
- Discrete Event Simulation: The Preferred Technique for Health Economic Evaluations?
- (2010) Jaime J. Caro et al. VALUE IN HEALTH
- Cost-Effectiveness of Genotype-Guided Warfarin Dosing for Patients With Atrial Fibrillation
- (2009) Amanda R. Patrick et al.
- Potential Clinical and Economic Outcomes of CYP2C9 and VKORC1 Genotype-Guided Dosing in Patients Starting Warfarin Therapy
- (2009) J H S You et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Dabigatran versus Warfarin in Patients with Atrial Fibrillation
- (2009) Stuart J. Connolly et al. NEW ENGLAND JOURNAL OF MEDICINE
- Estimation of the Warfarin Dose with Clinical and Pharmacogenetic Data
- (2009) NEW ENGLAND JOURNAL OF MEDICINE
- A Policy Model to Evaluate the Benefits, Risks and Costs of Warfarin Pharmacogenomic Testing
- (2009) Lisa M. Meckley et al. PHARMACOECONOMICS
- Pharmacogenomic trial design: use of a PK/PD model to explore warfarin dosing interventions through clinical trial simulation
- (2009) David H. Salinger et al. Pharmacogenetics and Genomics
- Genotype-guided dosing of coumarin derivatives: the European pharmacogenetics of anticoagulant therapy (EU-PACT) trial design
- (2009) Rianne MF van Schie et al. PHARMACOGENOMICS
- The largest prospective warfarin-treated cohort supports genetic forecasting
- (2008) M. Wadelius et al. BLOOD
- Pharmacology and Management of the Vitamin K Antagonists
- (2008) Jack Ansell et al. CHEST
- Initiation and persistence of warfarin or aspirin in patients with chronic atrial fibrillation in general practice: do the appropriate patients receive stroke prophylaxis?
- (2008) A. M. GALLAGHER et al. JOURNAL OF THROMBOSIS AND HAEMOSTASIS
- Risk factors for nonadherence to warfarin: results from the IN-RANGE study
- (2008) Alec B. Platt et al. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY
- Warfarin Pharmacogenetics
- (2008) Nita A Limdi et al. PHARMACOTHERAPY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreDiscover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversation